Amita Patnaik - Concepedia

Author

Amita Patnaik

South Texas Accelerated Research Therapeutics ORCID

Also Known As

A Patnaik, A. Patnaik, Amita Patnaik, Auro Varat Patnaik, Melinda Whiteside, Patnaik, A., Patnaik, Auro Varat

741

Publications

35.5K

Citations

H-Index

Concepts

All Affiliations

South Texas Accelerated Research Therapeutics The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, San Francisco

About

Amita Patnaik is an author at South Texas Accelerated Research Therapeutics specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	135	10.8K
2	Health Sciences	17	23	932
3	Engineering	1	1	116
4	Natural Sciences	1	1	366
5	Allergy	1	1	15

Amita Patnaik

225

Publications

34.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert, Antoni Ribas, Jedd D. Wolchok, The Lancet OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanoma	2014	1.7K
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, The Lancet Oncology OncologyMetronomic TherapyPathologyBronchial NeoplasmOpen-label Keynote-021 Study	2016	1.4K
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas, Omid Hamid, Adil Daud, JAMA	2016	1K
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2006	1K
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Omid Hamid, Caroline Robert, Adil Daud, Annals of Oncology	2019	920
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Amita Patnaik, Soonmo Peter Kang, Drew Rasco, Clinical Cancer Research	2015	767
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Journal of Clinical Oncology	2016	742
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Cancer Discovery	2016	740

Page 1